Finerenone (BAY94-8862) + Placebo

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Non-diabetic Chronic Kidney Disease

Conditions

Non-diabetic Chronic Kidney Disease

Trial Timeline

Sep 21, 2021 → Feb 2, 2026

NCT ID

NCT05047263

About Finerenone (BAY94-8862) + Placebo

Finerenone (BAY94-8862) + Placebo is a phase 3 stage product being developed by Bayer for Non-diabetic Chronic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05047263. Target conditions include Non-diabetic Chronic Kidney Disease.

What happened to similar drugs?

2 of 2 similar drugs in Non-diabetic Chronic Kidney Disease were approved

Approved (2) Terminated (0) Active (0)

✅Qutenza + PregabalinAstellas PharmaApproved

✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05047263	Phase 3	Completed	Sep 21, 2021	Feb 2, 2026	Non-diabetic Chronic Kidney Disease
NCT04795726	Pre-clinical	Completed	Mar 10, 2021	Jun 30, 2021	Diabetic Retinopathy
NCT02540993	Phase 3	Completed	Sep 17, 2015	Apr 14, 2020	Chronic Kidney Disease
NCT02545049	Phase 3	Completed	Sep 17, 2015	Feb 2, 2021	Diabetic Kidney Disease
NCT01874431	Phase 2	Completed	Jun 12, 2013	Aug 7, 2014	Diabetic Nephropathies

Competing Products

3 competing products in Non-diabetic Chronic Kidney Disease

See all competitors

Product	Company	Stage	Hype Score
Qutenza + Pregabalin	Astellas Pharma	Approved	43
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg	AstraZeneca	Approved	43
Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril	Novartis	Phase 2	27